Autologous peripheral blood mononuclear cell (aPBMC)

Autologous peripheral blood mononuclear cells (PBMCs) are a heterogeneous population of immune cells, including lymphocytes (T cells, B cells, and NK cells) and monocytes, that are harvested from a patient's own peripheral blood. These cells coordinate the body's immune response through complex mechanisms such as antigen presentation, cytokine signaling, and direct cytotoxicity. In the pharmaceutical industry, they are primarily used as a therapeutic substrate or delivery vehicle for personalized cell therapies. A prominent example is Sipuleucel-T, where a patient's PBMCs are activated ex vivo with a fusion protein to generate an immune response against prostate cancer. Beyond oncology, autologous PBMCs are investigated for regenerative purposes, such as in chronic limb ischemia, where they promote angiogenesis and modulate the local inflammatory environment to facilitate wound healing. Although essential to modern immunotherapy, they represent a multifaceted cellular entity rather than a discrete molecular target, necessitating specialized ex vivo processing and patient-specific quality control.

Other names

Peripheral blood mononuclear cellsPBMNCHuman mononuclear cells from peripheral bloodAutologous mononuclear cellsPBMC

Autologous peripheral blood mononuclear cells function as a therapeutic modality or cellular vehicle rather than a single molecular target; they are isolated via leukapheresis, modified or activated ex vivo (e.g., through antigen pulsing or genetic silencing), and re-infused to stimulate antigen-specific T-cell responses or promote tissue repair.